​

Aquestive Therapeutics (AQST) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AQST Stock Forecast

Aquestive Therapeutics (AQST) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $10.00, with a high of $12.00 and a low of $6.00. This represents a 134.19% increase from the last price of $4.27.

$2 $4 $6 $8 $10 $12 High: $12 Avg: $10 Low: $6 Last Closed Price: $4.27

AQST Stock Rating

Aquestive Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 10 Strong Sell Sell Hold Buy Strong Buy

AQST Price Target Upside V Benchmarks

TypeNameUpside
StockAquestive Therapeutics134.19%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks22.70%

Price Target Trends

1M3M12M
# Anlaysts-23
Avg Price Target-$9.00$10.00
Last Closing Price$4.27$4.27$4.27
Upside/Downside-110.77%134.19%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2627---9
Feb, 2617---8
Jan, 2627---9
Dec, 2536---9
Nov, 2546---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 03, 2026Lake Street$6.00$4.1943.20%40.52%
Feb 02, 2026New Street$12.00$4.10192.68%181.03%
Oct 09, 2025JMP Securities$12.00$6.2093.55%181.03%
Mar 07, 2025Raymond James$7.00$2.65164.15%63.93%
Nov 06, 2024Thomas FlatenLoop Capital Markets$10.00$4.79108.77%134.19%
Jun 25, 2024Thomas FlatenLoop Capital Markets$7.00$2.31203.03%63.93%
Apr 11, 2024David AmsellemPiper Sandler$10.00$4.07145.70%134.19%
Mar 18, 2024Raghuram SelvarajuH.C. Wainwright$9.00$5.5163.34%110.77%
Mar 15, 2024Francois BriseboisOppenheimer$12.00$6.0997.04%181.03%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 02, 2026OppenheimerOutperformOutperformhold
Oct 09, 2025CitigroupOutperformOutperformhold
Sep 08, 2025OppenheimerOutperformOutperformhold
Mar 07, 2025Lake StreetBuyBuyhold
Dec 17, 2024Cantor FitzgeraldOverweightinitialise
Dec 02, 2024Lake StreetBuyBuyhold
Sep 30, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024OppenheimerOutperformOutperformhold
Jun 25, 2024Lake StreetBuyBuyhold
May 09, 2024Alliance Global PartnersBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.85$-1.12$-0.13$-0.51$-0.76---
Avg Forecast$-1.52$-1.05$-0.13$-0.44$-0.57$-0.45$-0.21$0.15
High Forecast$-1.40$-0.82$-0.11$-0.43$-0.45$-0.22$0.29$0.18
Low Forecast$-1.76$-1.19$-0.14$-0.45$-0.68$-0.62$-0.64$0.12
Surprise %21.71%6.67%-15.91%33.33%---

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$50.83M$47.68M$50.58M$57.56M$44.55M---
Avg Forecast$49.10M$47.40M$48.89M$58.81M$52.98M$78.33M$125.65M$187.35M
High Forecast$54.99M$52.60M$49.55M$60.90M$58.12M$81.56M$142.31M$212.19M
Low Forecast$46.05M$39.71M$48.13M$57.81M$47.41M$75.09M$106.58M$158.92M
Surprise %3.52%0.58%3.46%-2.13%-15.92%---

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-70.54M$-54.41M$-7.87M$-44.14M$-83.78M---
Avg Forecast$-93.35M$-64.06M$-7.87M$-26.72M$-34.74M$-25.76M$-29.90M$9.19M
High Forecast$-85.81M$-50.53M$-6.56M$-26.14M$-27.54M$-13.67M$17.54M$10.77M
Low Forecast$-107.90M$-73.19M$-8.75M$-27.31M$-41.94M$-37.85M$-38.98M$7.38M
Surprise %-24.44%-15.06%-65.15%141.18%---

AQST Forecast FAQ

Is Aquestive Therapeutics stock a buy?

Aquestive Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aquestive Therapeutics is a favorable investment for most analysts.

What is Aquestive Therapeutics's price target?

Aquestive Therapeutics's price target, set by 10 Wall Street analysts, averages $10 over the next 12 months. The price target range spans from $6 at the low end to $12 at the high end, suggesting a potential 134.19% change from the previous closing price of $4.27.

How does Aquestive Therapeutics stock forecast compare to its benchmarks?

Aquestive Therapeutics's stock forecast shows a 134.19% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the specialty & generic drug manufacturers stocks industry (22.70%).

What is the breakdown of analyst ratings for Aquestive Therapeutics over the past three months?

  • March 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Aquestive Therapeutics’s EPS forecast?

Aquestive Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.45, marking a -40.79% decrease from the reported $-0.76 in 2025. Estimates for the following years are $-0.21 in 2027, and $0.15 in 2028.

What is Aquestive Therapeutics’s revenue forecast?

Aquestive Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $78.32M, reflecting a 75.83% increase from the reported $44.54M in 2025. The forecast for 2027 is $125.65M, and $187.35M for 2028.

What is Aquestive Therapeutics’s net income forecast?

Aquestive Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-25.758M, representing a -69.26% decrease from the reported $-83.784M in 2025. Projections indicate $-29.9M in 2027, and $9.19M in 2028.